Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

4.070 +0.010 (+0.25%)

Streaming Delayed Price Updated: 9:36 AM EST, Jan 23, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	8,711
Open	4.040
Bid (Size)	4.060 (100)
Ask (Size)	4.080 (3,000)
Prev. Close	4.060
Today's Range	4.040 - 4.070
52wk Range	1.810 - 4.170
Shares Outstanding	60,533,064
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

The trading volume of these stocks is deviating from the norm in today's session. ↗

January 22, 2026

Via Chartmill

LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders

January 21, 2026

From Halper Sadeh LLC

Via Business Wire

Performance

YTD	+107.7%	+107.7%
1 Month	+96.6%	+96.6%
3 Month	+73.2%	+73.2%
6 Month	+53.0%	+53.0%
1 Year	+48.0%	+48.0%

More News

Lisata Shares Nearly Double On Buyout Offer: Here Are The Details ↗

January 21, 2026

Via Stocktwits

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.

January 21, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

January 21, 2026

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics (NASDAQ:LSTA) Reports Narrower-Than-Expected Q3 2025 Loss ↗

November 06, 2025

Via Chartmill

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’

November 06, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

October 30, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

November 04, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

October 08, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

September 29, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 02, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

July 31, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 21, 2025

Via Benzinga

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

July 15, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

July 17, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

June 26, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

June 17, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics to Present at the 2025 BIO International Convention

June 11, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 08, 2025

From Lisata Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Lisata Therapeutics, Inc. - Common Stock publicly traded?

Yes, Lisata Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Lisata Therapeutics, Inc. - Common Stock trade on?

Lisata Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Lisata Therapeutics, Inc. - Common Stock?

The ticker symbol for Lisata Therapeutics, Inc. - Common Stock is LSTA on the Nasdaq Stock Market

What is the current price of Lisata Therapeutics, Inc. - Common Stock?

The current price of Lisata Therapeutics, Inc. - Common Stock is 4.070

When was Lisata Therapeutics, Inc. - Common Stock last traded?

The last trade of Lisata Therapeutics, Inc. - Common Stock was at 01/23/26 09:36 AM ET

What is the market capitalization of Lisata Therapeutics, Inc. - Common Stock?

The market capitalization of Lisata Therapeutics, Inc. - Common Stock is 246.37M

How many shares of Lisata Therapeutics, Inc. - Common Stock are outstanding?

Lisata Therapeutics, Inc. - Common Stock has 246M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.